NCT01045538View on ClinicalTrials.gov

Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 29, 2016

Study Completion Date

April 30, 2016

Conditions
Gastric CancerHistone Deacetylase Inhibitor
Interventions
DRUG

Vorinostat, capecitabine, and cisplatin

Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER